Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Brazen Capital is a venture capital firm founded in 2021 and based in Torrance, California. The firm is dedicated to supporting the next generation of scientist-CEOs, particularly in the human health sector. Led by W. Shawn Carbonell, MD, PhD, and Monica Berrondo, PhD, the team brings a wealth of experience from their backgrounds in laboratory research and startup creation. This unique perspective allows them to understand the challenges faced by technical founders transitioning from scientific research to successful company-building.
As of now, Brazen Capital is actively investing in early-stage companies, focusing on proof-of-concept projects that require capital to validate their scientific innovations. The firm emphasizes diversity by prioritizing investments in underrepresented and outlier founder teams. Although specific metrics such as fund size and portfolio count are not disclosed, Brazen Capital is recognized for its hands-on approach and commitment to guiding founders through the complexities of the healthcare landscape.
Brazen Capital primarily invests in early-stage human health companies, particularly those led by scientist-founders. The firm targets seed and Series A stages, with check sizes ranging from $100,000 to $5 million. Their investment strategy emphasizes proof-of-concept funding, which is crucial for validating scientific innovations and bringing them to market. This focus aligns with their mission to support underrepresented founders and foster diversity within the biotech and life sciences sectors.
The firm seeks to partner with founders who possess deep scientific expertise and are working on innovative solutions in healthcare and biotech. Brazen Capital's investment thesis is centered around helping these scientist-CEOs navigate the transition from laboratory research to successful business ventures. The team’s extensive experience in launching and scaling biotech startups enables them to provide valuable insights and strategic guidance throughout the investment process.
Currently, Brazen Capital does not have a verified portfolio of companies. However, the firm is associated with OncoSynergy, a startup founded by Shawn Carbonell that developed a novel cancer drug candidate. This connection highlights the firm's commitment to supporting innovative health solutions, even though no current portfolio companies have been publicly listed.
While Brazen Capital is still in the early stages of building its portfolio, its focus on scientist-led ventures positions it to attract promising startups in the healthcare and biotech sectors. The firm’s emphasis on proof-of-concept funding suggests that it will likely engage with companies that are at the forefront of scientific innovation and require capital to advance their projects.
W. Shawn Carbonell, MD, PhD - Founder & Managing Partner. Shawn has a background in laboratory research and previously founded OncoSynergy, where he raised over $20 million for a novel cancer drug candidate that reached Phase I clinical trials. His expertise lies in translating scientific research into viable business ventures.
Monica Berrondo, PhD - Partner. Monica is recognized for her contributions to the biotech field and has experience in launching startups based on her laboratory research. Her role at Brazen Capital focuses on supporting scientist-founders in navigating the complexities of the healthcare landscape.
Janet Escobar - Associate. Janet is part of the Brazen Capital team, contributing to the firm's investment activities. Specific details about her background were not verified, but she is listed as an associate in the firm's operations.
To pitch Brazen Capital, founders should use the contact page available at brazen.capital/contact. It is recommended to include a comprehensive pitch deck that outlines the scientific innovation, the founding team’s expertise, and the business model. Founders should expect a response time of several weeks, as the firm evaluates pitches based on their investment criteria.
Warm introductions are preferred, especially from individuals within the biotech or healthcare sectors. This can enhance the likelihood of receiving a favorable review of the pitch.
As of now, there have been no recent public announcements or activities reported for Brazen Capital since its founding in 2021. The firm is actively investing but has not disclosed specific portfolio companies or recent deals. The focus remains on supporting scientist-CEOs in the human health sector, particularly through proof-of-concept funding.
Future updates may include new investments or partnerships as Brazen Capital continues to build its portfolio and engage with innovative health startups.
What are Brazen Capital's investment criteria?
Brazen Capital focuses on early-stage human health companies, particularly those led by scientist-founders. The firm invests in seed and Series A stages, with check sizes ranging from $100,000 to $5 million. They prioritize proof-of-concept projects that require funding to validate scientific innovations.
How can I pitch to Brazen Capital?
Founders can pitch to Brazen Capital through their contact page at brazen.capital/contact. It is advisable to include detailed information about the scientific innovation, the team’s expertise, and the market potential of the venture.
What makes Brazen Capital different from other VC firms?
Brazen Capital is distinct in its focus on scientist-CEOs and underrepresented founder teams in the human health sector. The firm’s partners have firsthand experience in launching startups based on laboratory research, providing a unique perspective and hands-on support to their portfolio companies.
What geographic areas does Brazen Capital focus on?
The firm primarily invests in North America, specifically within the United States. Their focus on the Torrance area and broader U.S. market allows them to engage with a diverse range of health startups.
What type of support does Brazen Capital provide to its portfolio companies?
Brazen Capital offers not only financial support but also strategic guidance to its portfolio companies. The team’s extensive experience in the biotech sector enables them to assist founders in navigating the complexities of financing, clinical milestones, and scaling their businesses.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.